The workshop will cover a range of key issues, including taxonomy reclassification for the lactobacillus genus, the implications of the Nagoya Protocol, updates from Brazil and Canada, advances in next generation analytical tools, updates from the USP Probiotics Expert Panel, and the Food Safety Modernization Act (FSMA).
“A must-attend event”
The third IPA DC workshop in collaboration with the US Pharmacopeia will take place on Thursday, October 25 in Bethesda, MD, and brings together key industry stakeholders and federal regulators.
George Paraskevakos, IPA’s executive director, will open the event with IPA’s perspective on the probiotic market.
“The IPA D.C. Workshop has always been US-centric and that continues this year, with considerations around FSMA and possible discussion around the new discretionary guidance issued from the FDA, but this year we will have international content as well,” explained Paraskevakos. “We have presenters discussing the taxonomy issue,Nagoya Protocol and regulatory changes in other countries. These are significant issues which the US should keep an eye on and this includes the regulators as well.
“This is the third year and we’ve established the IPA D.C. Workshop as a key date on the probiotics calendar. Stakeholders are always waiting for it and there is a lot of interest. We’ve become a must-attend event, bringing stakeholders to D.C. to meet with federal representatives and to network with industry peers. This particular event hasinspired similar one day workshops for IPA around the world, and in 2019 we are planning a return to the US, three for the Latin America region and Australia also,” he added.
According to the event website: “Probiotics are unique in every way, from the manufacturing processes, storage & stability needs as well as the analytical requirements to touch but on a few areas. Careful consideration must be taken when it comes to looking at how regulators view their inclusion into guidance and guidelines. Probiotics cannot be blanketed into all the other food and dietary supplement categories when creating definitions on how industry should conduct themselves.
“Hence the workshop presents an excellent opportunity in opening dialogue and possible collaborations in looking at how these friendly organisms can be considered within these regulations.”
For more information and to register, please click HERE.
Click on the following link to read our coverage of the 2017 workshop: The 18 things we learned from the IPA’s DC Workshop 2017
Program highlights include:
Nagoya Protocol: Dr Markus Wyss, Director Global Regulatory Affairs, DSM Nutritional Products Ltd
Taxonomy reclassification: Dr Elisa Salvetti, Senior Post Doctoral Fellow, University of Verona (Italy)
FSMA: Larisa Pavlick, VP – Regulatory & Compliance, United Natural Products Alliance (UNPA) & Dr Amy Smith, Senior Manager, Regulatory & Scientific Affairs, DuPont Nutrition & Health
Update from the USP Probiotics Expert Panel: Dr Mary Ellen Sanders, Executive Science Officer, ISAPP, & Chair of the USP Probiotics Expert Panel
Updates from the IPA committees, including Dr Jessica Terhaar, IPA’s Director of Scientific Affairs & Kevin Mehring, IPA Manufacturing Committee Chair and President & CEO, UAS Labs